Skip to content
Main menu hidden.

Image: Barbara Sixt, Eva-Maria Diehl, Copyright Barbara Sixt, The Laboratory for Molecular Infection Medicine Sweden, MIMS. The picture may only be used for information about the publication of Barbara Sixt in PLOS ONE: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224324 corresponding author: barbara.sixt@umu.se

Åsa Gylfe Lab

Research group We research about novel antibacterial strategies for treatment of Chlamydia.

Chlamydia are significant human pathogens, causing infertility and blindness globally. There are more than 100 million annual cases of sexually transmitted C. trachomatis worldwide and almost as many people receive treatment for trachoma, a blinding eye infection. Treatment options are limited to broad-spectrum antibiotics that select for antibiotic resistance in other human pathogenic bacteria.Chlamydia readily develop resistance to antibiotics in vitro and it may become a clinical problem.

The goal of my research is to identify small molecules that can be further developed into new drugs against infections. The project can ultimately lead to new treatment options for Chlamydia and for other infections. At the same time, it can reduce the development of resistance and prevent globally occurring disabling diseases.

Head of research

Åsa Gylfe
Associate professor, consultant (attending) physician


Participating departments and units at Umeå University

Department of Clinical Microbiology, Faculty of Medicine

Research area

Infection biology
Latest update: 2023-02-23